Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardio Diagnostics Holdings (CDIO) Liabilities and Shareholders Equity (2021 - 2025)

Cardio Diagnostics Holdings' Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $8.8 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 96.12% year-over-year to $8.8 million; the TTM value through Sep 2025 reached $42.1 million, up 143.7%, while the annual FY2024 figure was $10.6 million, 137.89% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $8.8 million at Cardio Diagnostics Holdings, down from $10.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $65.8 million in Q3 2022 and bottomed at $1.1 million in Q4 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $7.7 million (2023), against an average of $17.8 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 467.11% in 2022 before it crashed 90.94% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.1 million in 2021, then surged by 467.11% to $6.2 million in 2022, then dropped by 28.6% to $4.5 million in 2023, then soared by 137.89% to $10.6 million in 2024, then decreased by 17.21% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for CDIO's Liabilities and Shareholders Equity are $8.8 million (Q3 2025), $10.4 million (Q2 2025), and $12.3 million (Q1 2025).